For the past quarter century investigative efforts on the bleeding tendency of uremia have served to focus most attention upon the platelet and its reactivity as the primary defect. In 1956 Lewis, Zucker and Ferguson reported that decreased platelet thromboplastic factor (platelet factor 3) and decreased prothrombin consumption were the most consistent abnormalities found in uremia (1) . Rath et al (2) confirmed these observations and Cahalane et al (3) were the first to demonstrate that the platelet abnormality of uremia could be transferred to normal platelets by incubation in uremic plasma. Willoughby and Crouch (4) underscored the qualitative defect of platelets by noting that mild thrombocytopenia, even when present, was not a sufficient explanation for the hemorrhagic diathesis in uremia. Subsequently, the nature of the platelet defect was defined further using techniques that measured platelet aggregation and adhesiveness.
In 1966, Salzman and Neri demonstrated that platelets in uremic blood passed through glass head filters without being retained (5) . They also observed that platelet aggregation in response to thrombin was impaired even though the aggregation response to ADP was normal. However, Horowitz et al (6) noted that platelet factor 3 activation following stimulation by ADP was suboptimal in uremic platelets. This effect could be mimicked in normal platelets by exposure to guanidinosuccinic acid (GSA) in concentrations known to be present in the serum of uremia patients (7) . They also showed that ADP, epinephrine and collagen induced platelet aggregation were impaired in uremia to a degree that correlated roughly with serum GSA levels, and that these defects were corrected by hemodialysis. Rabiner and Hrodek (8) performed similar studies using an assay of platelet factor 3 activated by celite. Their assay, which was also abnormal in uremia and corrected by hemodialysis, was unaffected by GSA but seemed to vary with the concentration of yet another uremic byproduct, phenolic acid (9) . These two studies indicated that platelet function could be affected deleteriously by at least two substances that accumulated in the blood of patients with uremia. While these studies did not refute each other, they did illustrate the complexity of the problem and raised the possibility that even more inhibitors of platelet function might be found in uremic blood. Moreover, the substantial incubation times required to induce defective function in normal platelets (GSA, 1 hour; phenolic acids 2-3 hours) indicated that a time-dependent alteration of platelet and/or drug was required before the inhibitory effect became apparent. Studies performed with urea and creatinine were equally intriguing.
In 1969, Eknoyan et al (10) demonstrated that urea in vivo induced platelet dysfucnction in normal subjects. Ten volunteers ingested urea in quantities sufficient to maintain serum levels between 60 and 120 mg%. After 24 hours of induced azotemia, five of six subjects had diminished platelet adhesiveness, four had a prolonged platelet thromboplastin generation test and two had a prolonged bleeding time. When azotemia was maintained for only ten hours, three of four subjects had diminished adhesiveness, one had altered platelet thromboplastin activity, but bleeding times remained normal. Similar results were obtained following oral administration of creatinine. Praga and Cortellaro (11) noted decreased platelet adhesivness in normal volunteers two to six hou rs after the ingestion of creatinine. This observation is concordant with the demonstrated correlation in uremic patients between serum creatinine levels above 6 mg% and the degree of impairment in platelet adhesiveness (12) . However, Horowitz (13) was unable to demonstrate any in vitro effect of creatinine or urea upon platelet function. The lack of in vitro effects again emphasizes that the production of platelet dysfunction by uremic byproducts is time-dependent. This conclusion is also consistent with the observation of Lindsay et al (12) that platelet function improve following 18 m 2 hours per week of hemodialysis but not when dialysis is limited to 12 m 2 hours per week. Thus, a number of substances may play a significant role in determining the platelet function defect of uremia. However, the inconsistencies between the in vitro and in vivo effects of these substances and the time interval they require to induce platelet dysfunction in vivo, indicates that other important factors in the genesis of the platelet defect of uremia remain to be defined.
The observation that diminished retention of platelets by glass bead columns in von Willebrand's disease could be corrected by cryoprecipitate (14) , suggested that an acquired abnormality of the high molecular weight fraction of factor VIII might explain the altered platelet adhesiveness in uremia. Studies performed by Kazatchine et al (15) appeared to confirm this hypothesis. They observed increased factor VIII antigen but decreased levels of von Willebrand factor activity in patients with uremia. They postulated that an acquired functional abnormality of factor VIII antigen might be responsible for the defective retention of uremic platelets by glass bead columns. However, subsequent studies (16) (17) (18) ) demonstrated increased rather than decreased von Willebrand's activity. This suggests that conditions in uremia favor increased rather than decreased platelet accretion to endothelial surfaces. Warrell et al (18) have suggested that the platelet defect in uremia may serve as a balance for the increased platelet adherence that might result from increased levels of von Willebrand's factor. If true, then improved platelet function may account for the accelerated atherosclerosis observed in patients on maintenance hemodialysis (19). Thus, changes in factor VIII related activities do not explain the platelet defect in uremia. However, recent studies of platelet and vascular prostaglandins suggest that this line of investigation might be more profitable.
In 1975 Hamberg et al (20) discovered thromboxane, a prostaglandin synthesized by platelets that has potent aggregating effects. This was followed by the discovery of prostacyclin, a vascular derived prostaglandin which is a potent inhibitor of platelet aggregation (21). Remuzzi et al demonstrated that the vascular tissues from uremic patients have increased prostacyclin synthesizing capacity (22) while uremic platelets (as shown by malodialdehyde measurements) have decreased thromboxane synthesis (23). Subsequently, Harter et al noted that platelet cyclooxygenase activity is also decreased in uremia (24). These studies indicate that the thromboxane prostacyclin balance in uremia may be tipped in favor of prostacyclin. This alteration may be the time-dependent derangement in platelet metabolism accomplished by «uremic toxins». For this reason, studies should be performed to determine whether the reported decrease in platelet thromboxane synthesis is caused by the toxic products that accumulate in uremia. If true, the many apparently dissociated platelet abnormalities described in uremia may finally arrange themselves into a coherent pathogenic mechanism. To the many complications of maintenance dialysis (1-3) must now be added the possibility of an increased risk of cancer (4) . Although early reports stressed the occurrence of tumors in immunosuppressed renal transplant patients, some of these malignancies were discovered so early after surgery as to give rise to the suspicion that they had developed during the period of uremia preceding the transplantation (5, 6) . In 1975 Matas et al provided the first convincing evidence of a link between uremia and malignancy, when they found nine cancers among 46 patients in the period of time they were uremic (3-36 months) (4). The 1.4 percent incidence rate was seven time higher than the expected yearly incidence rate in the agematched general population.
Although a few reports from Australia (7), Great Britain (8), France (9) , and the USA (10) have also recently appeared, it remains to be proven beyond doubt that cancer is frequent among uremic patients. The controversy about cancer in uremic is due in part to inadequate statistical analyses. Kinlen and coworkers (11) have pointed out that in previous studies the observed number of cancers was not compared with the expected number in a matched control population (4, 7, 8) . The larger series, such as the National (12) and European Dialysis Registries (3), give neither the time at risk and duration of exposure to uremia, the time at risk and duration of exposure to uremia, nor the necessary data about non-lethal cancers. In one study (8) the cancer incidence rate was incorrectly compared to death rates for the general population, thus invalidating any statistical conclusions. Skin cancers are also frequently included in these reports (7, 8) , thus introducing a bias toward detecting more tumors in these patients, who are examined more frequently than the control population.
In an attempt to clarify this issue, we examined the records of 151 patients receiving hemodialysis for an average of 66 months at the Seattle Veterans Administration Medical Center (13) . The duration of exposure to uremia and dialysis, age, sex, county of residence, and smoking history were determined in all cases. Nine cancers were found among 148 male patients, and six of these patients died from the malignancy. This finding of nine cancers is significantly higher (p < .0137) than the
